Nafoxidine HCl - CAS 1847-63-8
Catalog number:
Not Intended for Therapeutic Use. For research use only.
Molecular Formula:
Molecular Weight:
Estrogen Receptor/ERR
Nafoxidine HCl is the hydrochloride salt of nafoxidine. Nafoxidine, structurally related to Tamoxifen, is a non-steroidal partial estrogen antagonist.
Ordering Information
Catalog Number Size Price Stock Quantity
B0084-294307 1 g $299 In stock
Bulk Inquiry
Publictions citing BOC Sciences Products
  • >> More
Solid powder
1-[2-[4-(6-methoxy-2-phenyl-3,4-dihydronaphthalen-1-yl)phenoxy]ethyl]pyrrolidine;hydrochloride; NAFOXIDINEHYDROCHLORIDE; NafoxidineHCl; 1847-63-8; U11100A
Data not available, please inquire.
Canonical SMILES:
1.The evolution of nonsteroidal antiestrogens to become selective estrogen receptor modulators.
Craig Jordan V1, McDaniel R2, Agboke F2, Maximov PY2. Steroids. 2014 Nov;90:3-12. doi: 10.1016/j.steroids.2014.06.009. Epub 2014 Jun 17.
The discovery of the first nonsteroidal antiestrogen ethamoxytriphetol (MER25) in 1958, opened the door to a wide range of clinical applications. However, the finding that ethamoxytriphetol was a "morning after" pill in laboratory animals, energized the pharmaceutical industry to discover more potent derivatives. In the wake of the enormous impact of the introduction of the oral contraceptive worldwide, contraceptive research was a central focus in the early 1960's. Numerous compounds were discovered e.g., clomiphene, nafoxidine, and tamoxifen, but the fact that clinical studies showed no contraceptive actions, but, in fact, induced ovulation, dampened enthusiasm for clinical development. Only clomiphene moved forward to pioneer an application to induce ovulation in subfertile women. The fact that all the compounds were antiestrogenic made an application in patients to treat estrogen responsive breast cancer, an obvious choice. However, toxicities and poor projected commercial returns severely retarded clinical development for two decades.
2.Kinetic analysis of estrogen receptor/ligand interactions.
Rich RL1, Hoth LR, Geoghegan KF, Brown TA, LeMotte PK, Simons SP, Hensley P, Myszka DG. Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8562-7. Epub 2002 Jun 19.
Surface plasmon resonance biosensor technology was used to directly measure the binding interactions of small molecules to the ligand-binding domain of human estrogen receptor. In a screening mode, specific ligands of the receptor were easily discerned from nonligands. In a high-resolution mode, the association and dissociation phase binding responses were shown to be reproducible and could be fit globally to a simple interaction model to extract reaction rate constants. On average, antagonist ligands (such as tamoxifen and nafoxidine) were observed to bind to the receptor with association rates that were 500-fold slower than agonists (such as estriol and beta-estradiol). This finding is consistent with these antagonists binding to an altered conformation of the receptor. The biosensor assay also could identify subtle differences in how the same ligand interacted with two different isoforms of the receptor (alpha and beta). The biosensor's ability to determine kinetic rate constants for small molecule/protein interactions provides unique opportunities to understand the mechanisms associated with complex formation as well as new information to drive the optimization of drug candidates.
3.Estrogen receptor ligands affect mitochondrial activity in SH-SY5Y human neuroblastoma cells.
Simpson PB1, Woollacott AJ, Moneer Z, Rand V, Seabrook GR. Neuroreport. 2002 May 24;13(7):957-60.
We have studied the pharmacological regulation of mitochondrial activity in a human neuroblastoma cell line. Cyclosporin A was found to directly alter mitochondrial membrane potential and to decrease mitochondrial permeability as measured using calcein. The estrogen receptor ligands tamoxifen, nafoxidine and clomiphene were identified as agents which affect mitochondrial membrane potential in a cyclosporin A-like manner. Also when mitochondrial permeability was measured using calcein, tamoxifen, nafoxidine and clomiphene were effective in inhibiting dye loss from mitochondria. Nafoxidine and cyclosporin A inhibit effects of mastoparan on SH-SY5Y mitochondria. These studies indicate that estrogen receptor ligands appear to affect mitochondria in a cyclosporin A-like manner in human neuroblastoma cells.
4.Thermotropic liquid crystalline drugs.
Bunjes H1, Rades T. J Pharm Pharmacol. 2005 Jul;57(7):807-16.
Crystalline solids are characterized by long-range positional and orientational order in three dimensions, whereas amorphous liquids lack long-range order in any dimension. Liquid crystals (mesophases) show structural, mechanical and optical properties intermediate to those of crystalline solids and the amorphous, liquid state of matter. There are two principle types of liquid crystals: thermotropic liquid crystals (TLCs) and lyotropic liquid crystals (LLCs). TLCs can be formed by heating a crystalline solid or by cooling an isotropic melt of a TLC-forming molecule (mesogen). In the first part of this review the types of liquid crystals are defined and classified and the structural properties of mesogens are explained. In the second part, ten case studies of thermotropic mesomorphous drugs and pharmaceutically relevant molecules (arsphenamine, nafoxidine hydrochloride, L-660711, palmitoyl propranolol hydrochloride, penbutolol sulfate, itraconazole hydrochloride, fenoprofen sodium, fenoprofen calcium, ciclosporin and cholesteryl esters) are presented and their thermotropic mesomorphism is described.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Estrogen Receptor/ERR Products

CAS 72-33-3 Mestranol

(CAS: 72-33-3)

Mestranol is the 3-methyl ether of ethinylestradiol. It was the estrogen used in many of the first oral contraceptives.

CAS 979-32-8 Estradiol valerate

Estradiol valerate
(CAS: 979-32-8)

Estradiol valerate is a synthetic ester, specifically the 17-pentanoyl ester, of the natural estrogen, 17β-estradiol. It was introduced in the 1950s, and a...

(CAS: 1639042-08-2)

AZD9496 is a potent and orally bioavailable selective estrogen receptor downregulator and antagonist. AZD9496 can induce ERα degradation in breast cancer cell l...

CAS 89778-26-7 Toremifene Citrate

Toremifene Citrate
(CAS: 89778-26-7)

CAS 82640-04-8 Raloxifene HCl

Raloxifene HCl
(CAS: 82640-04-8)

Raloxifene is an oral selective estrogen receptor modulator (SERM) that has estrogenic actions on bone and anti-estrogenic actions on the uterus and breast. It ...

CAS 53-16-7 Estrone

(CAS: 53-16-7)

Estrone is one of the three naturally occurring estrogens, the others being estradiol and estriol. Estrone is synthesized from androstenedione by the aromatase ...

(CAS: 1446712-19-1)

SNG-1153, derived from icaritin which is purified from Epimedium Genus, modulates ER-α36 and induces β-catenin phosphorylation and then down-regulates β-catenin...

CAS 10540-29-1 Tamoxifen

(CAS: 10540-29-1)

Tamoxifen, a selective estrogen response modifier, is used in the advanced treatment of breast and ovarian cancer for it could be metabolized to two active ingr...

CAS 1845-11-0 Nafoxidine

(CAS: 1845-11-0)

Nafoxidine, a triphenylethylene nonsteroidal agent, is a partial estrogen antagonist.

CAS 1847-63-8 Nafoxidine HCl

Nafoxidine HCl
(CAS: 1847-63-8)

Nafoxidine HCl is the hydrochloride salt of nafoxidine. Nafoxidine, structurally related to Tamoxifen, is a non-steroidal partial estrogen antagonist.

CAS 54965-24-1 Tamoxifen Citrate

Tamoxifen Citrate
(CAS: 54965-24-1)

Tamoxifen Citrate is an antagonist of the estrogen receptor by competitive inhibition of estrogen binding, leading to a reduction in DNA synthesis and cellular ...

(CAS: 444643-64-5)

CHF-4227 is a selective estrogen receptor modulator, binds with high affinity to the human estrogen receptor-alpha and -beta (dissociation constant K(i) = 0.017...

CAS 50-27-1 Estriol

(CAS: 50-27-1)

Estriol is a metabolite of 17β-estradiol with much lower biological activity. It is the primary estrogen found in the urine. Large quantities of estriol and est...

CAS 434-03-7 Ethisterone

(CAS: 434-03-7)

Ethisterone is a progestogen hormone being considered to treat prostate cancer.It was the first orally-active progestin.

(CAS: 56632-39-4)

BHPI is an antagonist of estrogen receptor α (ERα), for it elicits sustained ERα-dependent activation of the endoplasmic reticulum (EnR) stress sensor.

CAS 56-53-1 Diethylstilbestrol

(CAS: 56-53-1)

Diethylstilbestrol, a synthetic nonsteroidal estrogen used in the treatment of menopausal and postmenopausal disorders.

CAS 313-06-4 Estradiol Cypionate

Estradiol Cypionate
(CAS: 313-06-4)

Estradiol cypionate is the 17 β-cyclopentylpropinate ester of estradiol, which inhibits ET-1 synthesis via estrogen receptor.

CAS 1428-67-7 Diarylpropionitrile

(CAS: 1428-67-7)

Diarylpropionitrile, also called as DPN, is a selective agonist of estrogen receptor β (ERβ) with a 70-fold higher relative binding affinity for ERβ(18%) versus...

CAS 152-43-2 Quinestriol

(CAS: 152-43-2)

Quinestriol, also called as Estrovis, is an orally active, long-acting, synthetic estrogen that is effective in hormone replacement therapy.

CAS 50-28-2 Estradiol

(CAS: 50-28-2)

Estradiol, or more precisely, 17β-estradiol, is a human sex hormone and steroid, and the primary female sex hormone. It is essential for the maintenance of fert...

Chemical Structure

CAS 1847-63-8 Nafoxidine HCl

Quick Inquiry

Verification code

Featured Items